Pfizer Inc (PFE) 33.24 $PFE
Eli Lilly's Breast Cancer Drug Gets Breakthrough Status
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 3:35PM CDT
Eli Lilly (LLY) received Breakthrough Therapy designation from the FDA for abemaciclib, being developed for the treatment of advanced breast cancer.
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), APRI: 1.65 (+0.03), LLY: 86.14 (+2.37)
Dow 30 Stock Roundup: Microsoft Launces Surface Book, Merck's Keytruda Approved for Lung Cancer
Swarup Gupta - Zacks Investment Research - Fri Oct 09, 1:59PM CDT
The Dow registered a record winning streak this week, boosted by energy stocks and the Fed's dovish stance.
MMM: 149.90 (+0.42), GE: 28.07 (+0.04), ADP: 85.24 (+0.12), IBM: 152.39 (+0.11), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DD: 56.18 (+0.05), MSFT: 47.11 (-0.34), BA: 139.70 (+0.66), CSCO: 27.91 (unch)
Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA(R) When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
Business Wire - Fri Oct 09, 12:45PM CDT
Pfizer Inc. (NYSE
FE) announced today that researchers presented for the first time data from a randomized, controlled Phase 2 study of its meningococcal serogroup B vaccine, TRUMENBA(R), coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines in adolescents. The data, which were released today in an oral presentation at IDWeek 2015(TM)in San Diego, are based on a study conducted in more than 2,600 healthy individuals 10 through 12 years of age that evaluated the safety, tolerability and immunogenicity of TRUMENBA when coadministered with MCV4 and Tdap. Data demonstrated that immune responses following TRUMENBA, MCV4 and Tdap vaccines given concomitantly were noninferior to immune responses to MCV4 and Tdap alone or TRUMENBA alone.
PFE: 33.24 (+0.15)
Stocks Rally as March Rate Hike Most Likely
at The Street - Thu Oct 08, 3:06PM CDT
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
AA: 10.26 (-0.75), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Genentech says its MS treatment worked in 3 studies
AP - Thu Oct 08, 2:33PM CDT
NEW YORK (AP) — Genentech released the results Thursday of three late-stage studies of a multiple sclerosis treatment that showed improved symptoms in patients compared with an established treatment.
PFE: 33.24 (+0.15)
Stocks Rise as Investors Interpret Fed Minutes as Dovish
at The Street - Thu Oct 08, 1:55PM CDT
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
AA: 10.26 (-0.75), SHAK: 44.05 (-2.17), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), FCAU: 15.67 (+0.17), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), CORT: 3.74 (-0.05)
5 Sector Favorites for Q3 Earnings & Their Hot ETFs
Sweta Killa - Zacks Investment Research - Thu Oct 08, 10:10AM CDT
These sector ETFs are expected to be the winners this earnings season.
DHI: 30.65 (unch), JNJ: 95.37 (+0.29), LEN: 51.33 (+0.26), JPM: 61.93 (-0.20), PFE: 33.24 (+0.15), ITB: 27.85 (-0.03), CARZ: 36.26 (+0.16), WFC: 52.14 (-0.40), BRK.B: 133.03 (-0.72), XLF: 23.24 (-0.15), IYT: 148.36 (+1.15), XLV: 68.44 (+0.31)
Global End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Clinical Trials Review H2, 2015
M2 - Thu Oct 08, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tbjjl/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" report to their offering. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Clinical Trial Overview of Top Companies - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca Plc - Shire Plc - Sanofi - Pfizer Inc. - Merck & Co., Inc. - DaVita HealthCare Partners Inc. - AbbVie Inc. Clinical Trial Overview of Top Institutes / Government - Isfahan University of Medical Sciences - Shiraz University of Medical Sciences - The National Institute of Allergy and Infectious Diseases - Vanderbilt University - The National Institute of Diabetes and Digestive and Kidney Diseases - University of Alberta - Ahvaz Jundishapur University of Medical Sciences - Centre Hospitalier Universitaire Vaudois - Columbia University - Creighton University For more information visit http://www.researchandmarkets.com/research/7t...age_kidney
SHPG: 200.90 (-1.85), PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)
Recession-Proofing Your Portfolio
at The Street - Wed Oct 07, 8:41AM CDT
The outlook on the U.S. economy is unclear, with recent data demonstrating too many contradictions: job growth remains weak, though consumer spending is strong.
GE: 28.07 (+0.04), DLTR: 63.36 (+1.28), GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), MCD: 102.76 (-0.19), XOM: 79.26 (-0.77), DG: 67.23 (+1.03), CAT: 71.30 (-0.54), KORS: 42.59 (-0.92), MO: 56.81 (+0.44), PG: 74.48 (+0.08), INTC: 32.14 (-0.38)
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Business Wire - Wed Oct 07, 6:00AM CDT
--Fast Track designation highlights the serious, unmet medical need that exists for patients with this disease
PFE: 33.24 (+0.15)
Vasculitis Pipeline Review, H2 2015 - 14 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxnvm5/vasculitis) has announced the addition of the "Vasculitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Aprogen, Inc. - ChemoCentryx, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hemostemix Ltd - K-Stemcell Co., Ltd. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Stempeutics Research Private Limited - Teijin Pharma Limited - XOMA Corporation Drug Profiles - ACP-01 - belimumab - beperminogene perplasmid - CCX-168 - gevokizumab - immune globulin (human) - Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - PF-1355 - rituximab biosimilar - Stempeucel - tocilizumab - Vascostem For more information visit http://www.researchandmarkets.com/research/pxnvm5/vasculitis
PFE: 33.24 (+0.15), CCXI: 6.45 (+0.02), GSK: 40.22 (+0.06), XOMA: 0.99 (+0.04)
Pfizer (PFE) Crosses Pivot Point Support at $33.03
Comtex SmarTrend(R) - Tue Oct 06, 10:45AM CDT
Pfizer (NYSE FE) has opened bearishly below the pivot of $33.45 today and has reached the first level of support at $33.03. Analysts will be watching for a cross of the next downside pivot targets of $32.57 and $31.69.
PFE: 33.24 (+0.15)
Global Smoking Cessation Pipeline Review, H2 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Oct 06, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2hqlt/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - Bioprojet SCR - Catalyst Biosciences, Inc. - CoMentis, Inc. - Embera NeuroTherapeutics, Inc. - FORUM Pharmaceuticals Inc. - GlaxoSmithKline Plc - Invion Limited - Johnson & Johnson - NAL Pharmaceuticals Ltd. - Pfizer Inc. - Pivot Pharmaceuticals Inc - Royalty Pharma - Selecta Biosciences, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (oxazepam metyrapone) - Anatabine - ARD-1600 - BP-1.4979 - Drugs to Inhibit FAAH for CNS Disorders - encenicline hydrochloride - GSK-598809 - GTS-21 - JNJ-39393406 - lorcaserin hydrochloride - nadolol - NFL-101 - NIC7-DT - Nicotine Vaccine - P-002 - PF-05402536 - PF-06413367 - SEL-068 - Small Molecule for Smoking Cessation and Appetite Suppression - Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation For more information visit http://www.researchandmarkets.com/research/n2..._cessation
JNJ: 95.37 (+0.29), PFE: 33.24 (+0.15), CBIO: 5.69 (+0.37), GSK: 40.22 (+0.06), ARNA: 2.19 (+0.14), ZYNE: 14.38 (-0.14)
Pfizer Rises 1.21% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 05, 3:56PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $33.00 to a high of $33.88. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $33.11 on volume of 31.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 33.24 (+0.15)
Look for Shares of Pfizer to Potentially Pullback after Yesterday's 1.21% Rise
Comtex SmarTrend(R) - Mon Oct 05, 3:55PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $33.00 to a high of $33.88. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $33.11 on volume of 31.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 33.24 (+0.15)
3 Stocks with Strong Competitive Positions
Brian Feroldi, George Budwell, and Cheryl Swanson, The Motley Fool - Motley Fool - Mon Oct 05, 3:15PM CDT
Image Source: Pixel-Sepp via pixabay. The key to investing is not assessing how much an industry is going to affect society, or how much it will grow, but rather determining the competitive advantage of any given company and, above all, the...
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), PFE: 33.24 (+0.15)
BMS paying $14.6M to settle SEC charges on payments in China
By MARCY GORDON - AP - Mon Oct 05, 2:09PM CDT
WASHINGTON (AP) — Bristol-Myers Squibb will pay $14.6 million to settle charges from U.S. regulators that its joint venture in China gave cash and other benefits to government health care providers to boost drug sales.
PFE: 33.24 (+0.15)
Global Anaplastic Large Cell Lymphoma (ALCL) Pipeline Review 2015 - 8 Companies & 14 Drug Profiles
M2 - Mon Oct 05, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dzdm64/anaplastic_large) has announced the addition of the "Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Akron Molecules AG - AstraZeneca Plc - Bayer AG - Celon Pharma Sp. z o.o. - Pfizer Inc. - Sareum Holdings Plc - Seattle Genetics, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles - AdIL-24 - AKR-302 - AKR-303 - AZD-3463 - brentuximab vedotin - CEP-28122 - CEP-37440 - copanlisib hydrochloride - crizotinib - Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - KRA-0008 - SH-7129 - Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology For more information visit http://www.researchandmarkets.com/research/dz...stic_large
SGEN: 39.38 (+0.87), PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), TEVA: 58.96 (-0.28)
Eli Lilly's Breast Cancer Drug Gets Breakthrough Status
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 3:35PM CDT
Eli Lilly (LLY) received Breakthrough Therapy designation from the FDA for abemaciclib, being developed for the treatment of advanced breast cancer.
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), APRI: 1.65 (+0.03), LLY: 86.14 (+2.37)
Dow 30 Stock Roundup: Microsoft Launces Surface Book, Merck's Keytruda Approved for Lung Cancer
Swarup Gupta - Zacks Investment Research - Fri Oct 09, 1:59PM CDT
The Dow registered a record winning streak this week, boosted by energy stocks and the Fed's dovish stance.
MMM: 149.90 (+0.42), GE: 28.07 (+0.04), ADP: 85.24 (+0.12), IBM: 152.39 (+0.11), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DD: 56.18 (+0.05), MSFT: 47.11 (-0.34), BA: 139.70 (+0.66), CSCO: 27.91 (unch)
Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA(R) When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
Business Wire - Fri Oct 09, 12:45PM CDT
Pfizer Inc. (NYSE
FE) announced today that researchers presented for the first time data from a randomized, controlled Phase 2 study of its meningococcal serogroup B vaccine, TRUMENBA(R), coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines in adolescents. The data, which were released today in an oral presentation at IDWeek 2015(TM)in San Diego, are based on a study conducted in more than 2,600 healthy individuals 10 through 12 years of age that evaluated the safety, tolerability and immunogenicity of TRUMENBA when coadministered with MCV4 and Tdap. Data demonstrated that immune responses following TRUMENBA, MCV4 and Tdap vaccines given concomitantly were noninferior to immune responses to MCV4 and Tdap alone or TRUMENBA alone. PFE: 33.24 (+0.15)
Stocks Rally as March Rate Hike Most Likely
at The Street - Thu Oct 08, 3:06PM CDT
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
AA: 10.26 (-0.75), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Genentech says its MS treatment worked in 3 studies
AP - Thu Oct 08, 2:33PM CDT
NEW YORK (AP) — Genentech released the results Thursday of three late-stage studies of a multiple sclerosis treatment that showed improved symptoms in patients compared with an established treatment.
PFE: 33.24 (+0.15)
Stocks Rise as Investors Interpret Fed Minutes as Dovish
at The Street - Thu Oct 08, 1:55PM CDT
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
AA: 10.26 (-0.75), SHAK: 44.05 (-2.17), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), FCAU: 15.67 (+0.17), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), CORT: 3.74 (-0.05)
5 Sector Favorites for Q3 Earnings & Their Hot ETFs
Sweta Killa - Zacks Investment Research - Thu Oct 08, 10:10AM CDT
These sector ETFs are expected to be the winners this earnings season.
DHI: 30.65 (unch), JNJ: 95.37 (+0.29), LEN: 51.33 (+0.26), JPM: 61.93 (-0.20), PFE: 33.24 (+0.15), ITB: 27.85 (-0.03), CARZ: 36.26 (+0.16), WFC: 52.14 (-0.40), BRK.B: 133.03 (-0.72), XLF: 23.24 (-0.15), IYT: 148.36 (+1.15), XLV: 68.44 (+0.31)
Global End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Clinical Trials Review H2, 2015
M2 - Thu Oct 08, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tbjjl/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" report to their offering. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Clinical Trial Overview of Top Companies - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca Plc - Shire Plc - Sanofi - Pfizer Inc. - Merck & Co., Inc. - DaVita HealthCare Partners Inc. - AbbVie Inc. Clinical Trial Overview of Top Institutes / Government - Isfahan University of Medical Sciences - Shiraz University of Medical Sciences - The National Institute of Allergy and Infectious Diseases - Vanderbilt University - The National Institute of Diabetes and Digestive and Kidney Diseases - University of Alberta - Ahvaz Jundishapur University of Medical Sciences - Centre Hospitalier Universitaire Vaudois - Columbia University - Creighton University For more information visit http://www.researchandmarkets.com/research/7t...age_kidney
SHPG: 200.90 (-1.85), PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)
Recession-Proofing Your Portfolio
at The Street - Wed Oct 07, 8:41AM CDT
The outlook on the U.S. economy is unclear, with recent data demonstrating too many contradictions: job growth remains weak, though consumer spending is strong.
GE: 28.07 (+0.04), DLTR: 63.36 (+1.28), GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), MCD: 102.76 (-0.19), XOM: 79.26 (-0.77), DG: 67.23 (+1.03), CAT: 71.30 (-0.54), KORS: 42.59 (-0.92), MO: 56.81 (+0.44), PG: 74.48 (+0.08), INTC: 32.14 (-0.38)
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Business Wire - Wed Oct 07, 6:00AM CDT
--Fast Track designation highlights the serious, unmet medical need that exists for patients with this disease
PFE: 33.24 (+0.15)
Vasculitis Pipeline Review, H2 2015 - 14 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxnvm5/vasculitis) has announced the addition of the "Vasculitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Aprogen, Inc. - ChemoCentryx, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hemostemix Ltd - K-Stemcell Co., Ltd. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Stempeutics Research Private Limited - Teijin Pharma Limited - XOMA Corporation Drug Profiles - ACP-01 - belimumab - beperminogene perplasmid - CCX-168 - gevokizumab - immune globulin (human) - Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - PF-1355 - rituximab biosimilar - Stempeucel - tocilizumab - Vascostem For more information visit http://www.researchandmarkets.com/research/pxnvm5/vasculitis
PFE: 33.24 (+0.15), CCXI: 6.45 (+0.02), GSK: 40.22 (+0.06), XOMA: 0.99 (+0.04)
Pfizer (PFE) Crosses Pivot Point Support at $33.03
Comtex SmarTrend(R) - Tue Oct 06, 10:45AM CDT
Pfizer (NYSE
FE) has opened bearishly below the pivot of $33.45 today and has reached the first level of support at $33.03. Analysts will be watching for a cross of the next downside pivot targets of $32.57 and $31.69. PFE: 33.24 (+0.15)
Global Smoking Cessation Pipeline Review, H2 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Oct 06, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2hqlt/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - Bioprojet SCR - Catalyst Biosciences, Inc. - CoMentis, Inc. - Embera NeuroTherapeutics, Inc. - FORUM Pharmaceuticals Inc. - GlaxoSmithKline Plc - Invion Limited - Johnson & Johnson - NAL Pharmaceuticals Ltd. - Pfizer Inc. - Pivot Pharmaceuticals Inc - Royalty Pharma - Selecta Biosciences, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (oxazepam metyrapone) - Anatabine - ARD-1600 - BP-1.4979 - Drugs to Inhibit FAAH for CNS Disorders - encenicline hydrochloride - GSK-598809 - GTS-21 - JNJ-39393406 - lorcaserin hydrochloride - nadolol - NFL-101 - NIC7-DT - Nicotine Vaccine - P-002 - PF-05402536 - PF-06413367 - SEL-068 - Small Molecule for Smoking Cessation and Appetite Suppression - Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation For more information visit http://www.researchandmarkets.com/research/n2..._cessation
JNJ: 95.37 (+0.29), PFE: 33.24 (+0.15), CBIO: 5.69 (+0.37), GSK: 40.22 (+0.06), ARNA: 2.19 (+0.14), ZYNE: 14.38 (-0.14)
Pfizer Rises 1.21% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 05, 3:56PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.00 to a high of $33.88. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $33.11 on volume of 31.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 33.24 (+0.15)
Look for Shares of Pfizer to Potentially Pullback after Yesterday's 1.21% Rise
Comtex SmarTrend(R) - Mon Oct 05, 3:55PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.00 to a high of $33.88. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $33.11 on volume of 31.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 33.24 (+0.15)
3 Stocks with Strong Competitive Positions
Brian Feroldi, George Budwell, and Cheryl Swanson, The Motley Fool - Motley Fool - Mon Oct 05, 3:15PM CDT
Image Source: Pixel-Sepp via pixabay. The key to investing is not assessing how much an industry is going to affect society, or how much it will grow, but rather determining the competitive advantage of any given company and, above all, the...
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), PFE: 33.24 (+0.15)
BMS paying $14.6M to settle SEC charges on payments in China
By MARCY GORDON - AP - Mon Oct 05, 2:09PM CDT
WASHINGTON (AP) — Bristol-Myers Squibb will pay $14.6 million to settle charges from U.S. regulators that its joint venture in China gave cash and other benefits to government health care providers to boost drug sales.
PFE: 33.24 (+0.15)
Global Anaplastic Large Cell Lymphoma (ALCL) Pipeline Review 2015 - 8 Companies & 14 Drug Profiles
M2 - Mon Oct 05, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dzdm64/anaplastic_large) has announced the addition of the "Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Akron Molecules AG - AstraZeneca Plc - Bayer AG - Celon Pharma Sp. z o.o. - Pfizer Inc. - Sareum Holdings Plc - Seattle Genetics, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles - AdIL-24 - AKR-302 - AKR-303 - AZD-3463 - brentuximab vedotin - CEP-28122 - CEP-37440 - copanlisib hydrochloride - crizotinib - Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - KRA-0008 - SH-7129 - Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology For more information visit http://www.researchandmarkets.com/research/dz...stic_large
SGEN: 39.38 (+0.87), PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), TEVA: 58.96 (-0.28)
